Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00658359




Registration number
NCT00658359
Ethics application status
Date submitted
9/04/2008
Date registered
15/04/2008
Date last updated
23/02/2018

Titles & IDs
Public title
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
Scientific title
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Secondary ID [1] 0 0
2008-002345-23
Secondary ID [2] 0 0
A3921050
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney Transplantation 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cyclosporine
Treatment: Drugs - CP-690,550
Treatment: Drugs - CP-690,550

Active comparator: Treatment Arm 1 - Treatment Arm 1 will also receive standard of care medications

Experimental: Treatment Arm 2 - Treatment Arm 2 will also receive standard of care medications

Experimental: Treatment Arm 3 - Treatment Arm 3 will also receive standard of care medications


Treatment: Drugs: Cyclosporine
Standard of care

Treatment: Drugs: CP-690,550
CP-690,550 tablets dosed BID Months 12-72

Treatment: Drugs: CP-690,550
CP-690,550 tablets dosed BID Months 12-72
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Kaplan-Meier Analysis of Percentage of Participants With Clinically Significant Infection by Visit
Timepoint [1] 0 0
Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Primary outcome [2] 0 0
Percentage of Participants With Malignancies
Timepoint [2] 0 0
Months 12 through 72.
Primary outcome [3] 0 0
Least Squares Means of Measured Glomerular Filtration Rate (GFR) (Iohexol Serum Clearance in Milliliters Per Minute [mL/Min])
Timepoint [3] 0 0
Month 36
Primary outcome [4] 0 0
Percentage of Participants With Progression of Chronic Allograft Lesions at Month 36
Timepoint [4] 0 0
Month 36
Primary outcome [5] 0 0
Kaplan-Meier Analysis of Percentage of Participants With First Biopsy Proven Acute Rejection (BPAR) by Visit
Timepoint [5] 0 0
Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Primary outcome [6] 0 0
Kaplan-Meier Analysis of Percentage of Participants With Treated Clinical Acute Rejection by Visit
Timepoint [6] 0 0
Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [1] 0 0
Kaplan-Meier Analysis of Percentage of Participants With Efficacy Failure by Visit
Timepoint [1] 0 0
Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [2] 0 0
Kaplan-Meier Analysis of Percentage of Participants With Combined Banff Rejection by Visit
Timepoint [2] 0 0
Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [3] 0 0
Kaplan-Meier Analysis of Percent of Participants With Graft Survival With Death Censored by Visit
Timepoint [3] 0 0
Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [4] 0 0
Kaplan-Meier Analysis of Percentage of Participants Surviving by Visit
Timepoint [4] 0 0
Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [5] 0 0
Percentage of Participants Discontinuing From the Study
Timepoint [5] 0 0
Months 12 through 72.
Secondary outcome [6] 0 0
Least Squares Means of Total Serum Cholesterol Levels (Milligrams Per Deciliter [mg/dL]) by Visit
Timepoint [6] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [7] 0 0
Least Squares Means of Total Serum Low Density Lipoprotein (LDL) Cholesterol Levels (mg/dL) by Visit
Timepoint [7] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [8] 0 0
Least Squares Means of Total Serum High Density Lipoprotein (HDL) Cholesterol Levels (mg/dL) by Visit
Timepoint [8] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [9] 0 0
Least Squares Means of Total Serum Triglycerides (mg/dL) by Visit
Timepoint [9] 0 0
Month 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [10] 0 0
Mean Absolute Neutrophil Counts (ANC) (Kelvin Per Millimeter Cubed [K/mm^3]) by Visit
Timepoint [10] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 and Follow-up
Secondary outcome [11] 0 0
Mean Hemoglobin (Hgb) (Grams Per Deciliter [g/dL]) by Visit
Timepoint [11] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 and Follow-up
Secondary outcome [12] 0 0
Mean Glycosylated Hemoglobin (HBA1c) (Percent [%]) by Visit
Timepoint [12] 0 0
Months 24, 36, 48, 60, 72
Secondary outcome [13] 0 0
Least Squares Means of Fasting Serum Glucose Levels (mg/dL) by Visit
Timepoint [13] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [14] 0 0
Percentage of Participants by Proteinuria Category by Visit
Timepoint [14] 0 0
Months 24, 36, 48, 60, 72 and Follow-up
Secondary outcome [15] 0 0
Least Square Means of Estimated GFR Calculated Using the Nankivell Equation by Visit
Timepoint [15] 0 0
Month 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [16] 0 0
Least Squares Means of Estimated GFR Calculated Using the Cockcroft-Gault Equation by Visit
Timepoint [16] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [17] 0 0
Least Squares Means of Estimated GFR (eGFR) (mL/Min/1.73 Square Meter [m^2]) Calculated by the Modification of Diet in Renal Disease (MDRD) Equation With Last Observation Carried Forward (LOCF) Plus Imputation (eGFR=0 for Graft Loss/Death) by Visit
Timepoint [17] 0 0
Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Secondary outcome [18] 0 0
Least Squares Means of Short Form 36 Version 2 (SF-36 V2) Component and Domain Scores at Months 24 and 36
Timepoint [18] 0 0
Months 24, 36
Secondary outcome [19] 0 0
Least Squares Means of End-Stage Renal Disease (ESRD) Symptom Checklist (SCL) -Transplantation Modules at Months 24 and 36
Timepoint [19] 0 0
Months 24, 36
Secondary outcome [20] 0 0
Least Squares Means of Severity of Dyspepsia Assessment (SODA) Subscales at Months 24 & 36
Timepoint [20] 0 0
Months 24, 36
Secondary outcome [21] 0 0
Mean Trough Levels of Tofacitinib by Visit
Timepoint [21] 0 0
Months 18 and 24 (-2 hours, predose, 1 hour, 2 hours), Month 30 (predose, 1 hour and 2 hours), Month 36 (predose, 1, 2, and 4 hours), Months 42, 48, 54, 60, 66, 72 (predose and 2 hours)
Secondary outcome [22] 0 0
Mean Trough Levels of Cyclosporine by Visit
Timepoint [22] 0 0
Predose: Months 18, 24, 36, 48, 60, 72

Eligibility
Key inclusion criteria
* Subjects who successfully completed Study A3921030
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects who are on the waiting list for a second kidney transplant or any non-renal organ transplants

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2015
Sample size
Target
Accrual to date
Final
178
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Westmead Hospital, Department of Renal Medicine - Westmead
Recruitment hospital [3] 0 0
Central Northern Adelaide Renal and Transplantation Service - Adelaide
Recruitment hospital [4] 0 0
The Queen Elizabeth Hospital - Woodville
Recruitment hospital [5] 0 0
Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
South Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Belgium
State/province [12] 0 0
Brussels
Country [13] 0 0
Belgium
State/province [13] 0 0
Leuven
Country [14] 0 0
Brazil
State/province [14] 0 0
RS
Country [15] 0 0
Brazil
State/province [15] 0 0
SP
Country [16] 0 0
Brazil
State/province [16] 0 0
Sao Paulo
Country [17] 0 0
Canada
State/province [17] 0 0
Alberta
Country [18] 0 0
Czechia
State/province [18] 0 0
Praha 4 Krc
Country [19] 0 0
France
State/province [19] 0 0
Paris Cedex 15
Country [20] 0 0
France
State/province [20] 0 0
Vandoeuvre Les Nancy
Country [21] 0 0
Germany
State/province [21] 0 0
Berlin
Country [22] 0 0
Italy
State/province [22] 0 0
RM
Country [23] 0 0
Italy
State/province [23] 0 0
Bologna
Country [24] 0 0
Korea, Republic of
State/province [24] 0 0
Seoul
Country [25] 0 0
Netherlands
State/province [25] 0 0
Rotterdam
Country [26] 0 0
Norway
State/province [26] 0 0
Oslo
Country [27] 0 0
Poland
State/province [27] 0 0
Wroclaw
Country [28] 0 0
Portugal
State/province [28] 0 0
Coimbra
Country [29] 0 0
Portugal
State/province [29] 0 0
Lisboa
Country [30] 0 0
Spain
State/province [30] 0 0
Barcelona

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00658359